ストックスクリーナーアプリを入手
6.8301
11.17%
-0.8699
前日終値:
$7.70
開ける：
$7.6
24時間の取引高:
181.13K
Relative Volume:
1.57
時価総額：
$857.46M
収益：
$36.86M
当期純損益:
$-171.67M
株価収益率:
-4.5534
EPS:
-1.5
ネットキャッシュフロー:
$-171.05M
1週間 パフォーマンス:
-23.85%
1か月 パフォーマンス:
-5.98%
6か月 パフォーマンス:
-57.75%
1年 パフォーマンス:
-86.97%
1日の値動き範囲:
$6.75
$7.60
1週間の範囲:
$6.75
$10.25
52週間の値動き範囲:
$6.4725
$70.75
Mersana Therapeutics Inc Stock (MRSN) Company Profile
MRSN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MRSN
Mersana Therapeutics Inc
|
6.88 | 38.39M | 36.86M | -171.67M | -171.05M | -1.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.20 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
566.64 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.94 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
596.51 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
297.79 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-06 | 開始されました | William Blair | Outperform |
| 2024-11-15 | 再開されました | Citigroup | Buy |
| 2024-03-19 | アップグレード | JP Morgan | Underweight → Neutral |
| 2024-02-29 | アップグレード | BTIG Research | Neutral → Buy |
| 2024-02-29 | アップグレード | Guggenheim | Neutral → Buy |
| 2024-02-29 | アップグレード | Wedbush | Neutral → Outperform |
| 2023-12-04 | アップグレード | Citigroup | Neutral → Buy |
| 2023-07-28 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2023-07-27 | ダウングレード | BTIG Research | Buy → Neutral |
| 2023-07-27 | ダウングレード | Citigroup | Buy → Neutral |
| 2023-07-27 | ダウングレード | Guggenheim | Buy → Neutral |
| 2023-07-27 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2023-07-27 | ダウングレード | Truist | Buy → Hold |
| 2023-07-27 | ダウングレード | Wedbush | Outperform → Neutral |
| 2023-06-16 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2023-06-15 | 開始されました | Guggenheim | Buy |
| 2023-03-16 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-01-20 | 開始されました | Citigroup | Buy |
| 2022-11-21 | 開始されました | Truist | Buy |
| 2021-10-15 | 再開されました | BTIG Research | Buy |
| 2021-08-30 | 開始されました | H.C. Wainwright | Buy |
| 2021-03-31 | 開始されました | Credit Suisse | Neutral |
| 2020-12-03 | 開始されました | Stifel | Buy |
| 2020-09-29 | 再開されました | JP Morgan | Neutral |
| 2020-04-29 | 開始されました | BTIG Research | Buy |
| 2020-01-21 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-03-11 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2018-11-14 | アップグレード | Leerink Partners | Mkt Perform → Outperform |
| 2018-05-08 | 開始されました | Robert W. Baird | Outperform |
| 2018-03-19 | ダウングレード | JP Morgan | Overweight → Neutral |
すべてを表示
Mersana Therapeutics Inc (MRSN) 最新ニュース
What is Mersana Therapeutics Inc. company’s growth strategyRapid profit acceleration - jammulinksnews.com
Should I hold or sell Mersana Therapeutics Inc. stock in 2025Exceptional stock performance - jammulinksnews.com
What are the latest earnings results for Mersana Therapeutics Inc.Maximize returns with disciplined trading approaches - jammulinksnews.com
Does Mersana Therapeutics Inc. stock perform well during market downturnsBreakthrough capital growth - jammulinksnews.com
Why Mersana Therapeutics Inc. stock attracts strong analyst attentionControlled Risk High Reward Plan - Metal.it
How Mersana Therapeutics Inc. stock performs during market volatilityTop Growth Low Risk Stocks - metal.it
MRSN Trading Halted Due to Pending News - GuruFocus
What analysts say about Mersana Therapeutics Inc. stockSuperior stock selection - PrintWeekIndia
Mersana Therapeutics Presents Positive Phase 1 Data for Cancer Drug Emi-Le at ASCO 2025 - Insider Monkey
What drives Mersana Therapeutics Inc. stock priceRapid wealth accumulation - PrintWeekIndia
Will Mersana Therapeutics Inc. stock split in the near futureFree Investment Case Studies - jammulinksnews.com
Mersana Therapeutics to execute 1-for-25 reverse stock split - MSN
Mersana To Implement 1-for-25 Reverse Stock Split To Regain Nasdaq Compliance - Nasdaq
Mersana Therapeutics Implements Reverse Stock Split to Meet Nasdaq Listing Requirements - AInvest
Mersana Therapeutics stock tumbles on 1-for-25 reverse split plan - Investing.com Australia
Mersana Therapeutics stock tumbles on 1-for-25 reverse split plan By Investing.com - Investing.com South Africa
Mersana Therapeutics to implement 1-for-25 reverse stock split Friday - Investing.com Australia
Mersana Therapeutics to implement 1-for-25 reverse stock split Friday By Investing.com - Investing.com South Africa
Mersana Therapeutics (MRSN) Implements 1-for-25 Reverse Stock Sp - GuruFocus
Mersana Therapeutics Announces Reverse Stock Split - TipRanks
Mersana Therapeutics to implement 1-for-25 reverse stock split - Investing.com India
Mersana Therapeutics to implement 1-for-25 reverse stock split By Investing.com - Investing.com Nigeria
Mersana (MRSN) Announces 1-for-25 Reverse Split to Retain Nasdaq Listing - Stock Titan
Mersana Therapeutics Announces 1-for-25 Reverse Stock Split - GlobeNewswire
Mersana's 1:25 Reverse Split Aims to Save Nasdaq Listing: Key Details for Investors - Stock Titan
Mersana Therapeutics Inc. Stock Analysis and ForecastSuperior stock growth - Autocar Professional
MRSN: Riding the Market Waves of Growth and Decline in 2025 - investchronicle.com
12 Best Penny Stocks Under $1 to Buy Now - Insider Monkey
Is Mersana Therapeutics Inc. a good long term investmentPowerful growth strategies - jammulinksnews.com
Mersana Therapeutics Inc (MRSN) 財務データ
収益
当期純利益
現金流量
EPS
Mersana Therapeutics Inc (MRSN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Mandelia Ashish | VP, Chief Accounting Officer |
Jan 16 '25 |
Sale |
0.58 |
3,554 |
2,061 |
57,519 |
| Protopapas Anna | Director |
Jan 15 '25 |
Option Exercise |
0.00 |
21,250 |
0 |
176,678 |
| Protopapas Anna | Director |
Jan 16 '25 |
Sale |
0.58 |
8,637 |
5,009 |
168,041 |
| Lowinger Timothy B | SVP, Chief Sci.&Tech. Officer |
Jan 15 '25 |
Option Exercise |
0.00 |
19,791 |
0 |
265,721 |
| Lowinger Timothy B | SVP, Chief Sci.&Tech. Officer |
Jan 16 '25 |
Sale |
0.58 |
8,048 |
4,668 |
257,673 |
| Huber Martin H. Jr. | President, CEO |
Jan 15 '25 |
Option Exercise |
0.00 |
11,062 |
0 |
127,389 |
| Huber Martin H. Jr. | President, CEO |
Jan 16 '25 |
Sale |
0.58 |
4,514 |
2,618 |
122,875 |
| DeSchuytner Brian | SVP, COO & CFO |
Jan 15 '25 |
Option Exercise |
0.00 |
20,833 |
0 |
129,863 |
| DeSchuytner Brian | SVP, COO & CFO |
Jan 16 '25 |
Sale |
0.58 |
8,470 |
4,913 |
121,393 |
| Carvajal Alejandra | SVP, Chief Legal Officer |
Jan 15 '25 |
Option Exercise |
0.00 |
12,500 |
0 |
83,392 |
0.49%
1.18%
大文字化:
|
ボリューム (24 時間):